Therefore, in the most recent EULAR recommendations (Hatemi et al., 2018), IFN-α is one of the recommended agents for patients with recurrent episodes of acute sight-threatening uveitis based on its efficacy in inducing rapid ocular inflammation remission, preventing recurrences, and maintaining useful vision in medium to long terms. This evidence concerns the gene IFNA1 and uveitis.